These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 24315100)

  • 41. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
    Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
    J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
    Dhawan M; Ryan CJ
    Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
    Korpal M; Korn JM; Gao X; Rakiec DP; Ruddy DA; Doshi S; Yuan J; Kovats SG; Kim S; Cooke VG; Monahan JE; Stegmeier F; Roberts TM; Sellers WR; Zhou W; Zhu P
    Cancer Discov; 2013 Sep; 3(9):1030-43. PubMed ID: 23842682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
    Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
    Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.
    Gentile E; Hahn AW; Song JH; Hoang A; Shepherd PDA; Ramachandran S; Navone NM; Efstathiou E; Titus M; Corn PG; Lin SH; Logothetis CJ; Panaretakis T
    Cancer Res Commun; 2023 Dec; 3(12):2531-2543. PubMed ID: 37930121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
    Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
    Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
    Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
    Porter LH; Bakshi A; Pook D; Clark A; Clouston D; Kourambas J; ; Goode DL; Risbridger GP; Taylor RA; Lawrence MG
    J Pathol; 2021 Jun; 254(2):121-134. PubMed ID: 33620092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computationally guided discovery of novel non-steroidal AR-GR dual antagonists demonstrating potency against antiandrogen resistance.
    Chai X; Hu XP; Wang XY; Wang HT; Pang JP; Zhou WF; Liao JN; Shan LH; Xu XH; Xu L; Xia HG; Hou TJ; Li D
    Acta Pharmacol Sin; 2023 Jul; 44(7):1500-1518. PubMed ID: 36639570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen Receptor-Interacting Proteins in Prostate Cancer Development and Therapy Resistance.
    Culig Z; Puhr M
    Am J Pathol; 2024 Mar; 194(3):324-334. PubMed ID: 38104650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Niu Y; Guo C; Wen S; Tian J; Luo J; Wang K; Tian H; Yeh S; Chang C
    Cancer Lett; 2018 Dec; 439():47-55. PubMed ID: 30227222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.
    Qian C; Yang Q; Rotinen M; Huang R; Kim H; Gallent B; Yan Y; Cadaneanu RM; Zhang B; Kaochar S; Freedland SJ; Posadas EM; Ellis L; Di Vizio D; Morrissey C; Nelson PS; Brady L; Murali R; Campbell MJ; Yang W; Knudsen BS; Mostaghel EA; Ye H; Garraway IP; You S; Freeman MR
    Nucleic Acids Res; 2024 Jul; 52(13):7740-7760. PubMed ID: 38932701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists.
    Wilson VS; Bobseine K; Lambright CR; Gray LE
    Toxicol Sci; 2002 Mar; 66(1):69-81. PubMed ID: 11861974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.
    Cerasuolo M; Maccarinelli F; Coltrini D; Mahmoud AM; Marolda V; Ghedini GC; Rezzola S; Giacomini A; Triggiani L; Kostrzewa M; Verde R; Paris D; Melck D; Presta M; Ligresti A; Ronca R
    Cancer Res; 2020 Apr; 80(7):1564-1577. PubMed ID: 32029552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
    Shiota M; Ushijima M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Kajioka S; Eto M
    Prostate; 2019 Jul; 79(10):1147-1155. PubMed ID: 31077419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.